It emerged late last week that pharmaceutical firm Bristol-Myers Squibb's settlement over claims that it illegally boosted its share price by making false claims regarding one of its experimental drugs has received preliminary approval.
The firm announced last week that it will create a settlement fund to address a class action lawsuit brought by investors who purchased its stocks between October 1999 and March 2002.
Vanlev, an experimental blood-pressure drug, was much vaunted by Bristol-Myers (with predicted sales of more than $1 billion), despite the fact that potentially significant side effects were known about in the mid-to-late nineties.
However, it was not until April 2000 that the firm withdrew its request for approval of the drug by the FDA, sparking a significant drop in the firm's share prices which stung investors.
In announcing the settlement, Bristol-Myers Squibb has neither admitted nor denied wrongdoing.
.
|
Archive | Resources | Partners | Site Map | Links | Newsletter Archive | Contact | RSS Feeds | About | Syndication | Advertising & Marketing | Recruitment | Terms & Conditions | Privacy
Copyright © 2012 - All Rights Reserved - Tax-News.com
IMPORTANT NOTICE: Tax-News.com has taken reasonable care in sourcing and presenting the information contained on this site, but accepts no responsibility for any financial or other loss or damage that may result from its use. In particular, users of the site are advised to take appropriate professional advice before committing themselves to involvement in offshore jurisdictions, offshore trusts or offshore investments.
Write a comment